ClinicalTrials.gg
Active, not recruitingNCT05518045Updated Sep 3, 2026

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

A Phase 1/2 interventional study of LM-108 and Toripalimab in Advanced Solid Tumor, sponsored by LaNova Medicines Limited. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
392
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A Phase I/II, Open-Label, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108, an Anti-CCR8 Monoclonal Antibody, as Monotherapy or in Combination with Antitumor Therapies in Patients with Advanced Solid Tumors

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status of 0-1.
  2. Histological or cytological confirmation of recurrent or advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
  3. At least one for expansion cohorts per (RECIST) v1.1.
  4. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Have received anti-CCR8 drug treatment or other clinical study drug or treatment not on the market within 28 days prior to the first dose.
  2. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of v5.0.
  3. Subjects with uncontrolled tumor-related pain.
  4. Subjects with known .
  5. Uncontrollable clinical third luminal effusion.
  6. Known history of disease.
  7. Use of any within 28 days.
  8. Have severe cardiovascular disease.
  9. Uncontrolled or severe illness.
  10. History of immunodeficiency disease.
  11. Active which are likely to require the treatment.
  12. female.
  13. Have psychiatric illness or disorders.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
392 participants (estimated)

Study arms

  • Experimental
    LM-108 Dose Escalation

    Drug: LM-108

  • Experimental
    LM-108 Dose Expansion

    Drug: LM-108

  • Experimental
    LM-108 combination dose expansion

    Drug: LM-108 · Drug: Toripalimab

Interventions

06

What researchers measure

Primary outcomes

  1. Phase I Dose Escalation:Incidence of adverse events (AEs)

    Time frame: 152 Weeks

  2. Phase I Dose Escalation:Incidence of dose-limiting toxicity (DLT)

    Time frame: 152 Weeks

  3. Phase I Dose Escalation:Incidence of serious adverse event (SAE)

    Time frame: 152 Weeks

  4. Phase I Dose Escalation:Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.

    Time frame: 152 Weeks

  5. Phase II Dose Expansion Cohort:Objective Response Rate (ORR) Evaluated by Researchers Based on RECIST v1.1

    Time frame: 152 Weeks

Secondary outcomes

  1. Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax) for LM-108

    Time frame: 152 Weeks

  2. PK Parameter: Time of Maximum Observed Concentration (Tmax) for LM-108

    Time frame: 152 Weeks

  3. PK Parameter: Area Under the Concentration-time Curve (AUC) for LM-108

    Time frame: 152 Weeks

  4. PK Parameter: Steady State Maximum Concentration (Cmax,ss)

    Time frame: 152 Weeks

  5. PK Parameter: Steady State Minimum Concentration (Cmin, ss)

    Time frame: 152 Weeks

  6. PK Parameter: Systemic Clearance at Steady State (CLss)

    Time frame: 152 Weeks

  7. PK Parameter: Accumulation Ratio (Rac)

    Time frame: 152 Weeks

  8. PK Parameter: Elimination Half-life (t 1/2)

    Time frame: 152 Weeks

  9. PK Parameter: Volume of Distribution at Steady-State (Vss)

    Time frame: 152 Weeks

  10. PK Parameter: Degree of Fluctuation (DF)

    Time frame: 152 Weeks

  11. Incidence of anti-drug antibodies to LM-108

    Time frame: 152 Weeks

  12. Phase I Dose Escalation:Preliminary anti-tumor activity:Objective Response Rate,Duration of Response, Disease Control Rate,Progression-Free Survival,and Overall Survival evaluated according to the Response Evaluation Criteria in Solid Tumors (RECISTv1.1)

    Time frame: 152 Weeks

  13. Phase I Dose Escalation:Correlation between biomarker expression levels (FoxP3, PD-L1, CCR8, CD8) and the anti-tumor activity of LM-108 as monotherapy or in combination with toripalimab.

    Time frame: 152 Weeks

  14. Phase II Dose Expansion Cohort:Antitumor Activity: Duration of Response (DOR), Disease Control Rate (DCR), Progression-Free Survival (PFS), and Overall Survival (OS) evaluated by investigators based on RECIST v1.1;

    Time frame: 152 Weeks

  15. Phase II Dose Expansion Cohort:Objective Response Rate (ORR), DOR, DCR, and PFS evaluated by the Independent Review Committee (IRC) based on RECIST v1.1

    Time frame: 152 Weeks

  16. Phase II Dose Expansion Cohort:Incidence of adverse events (AEs)

    Time frame: 152 Weeks

  17. Phase II Dose Expansion Cohort:Incidence of serious adverse event (SAE)

    Time frame: 152 Weeks

  18. Phase II Dose Expansion Cohort:Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.

    Time frame: 152 Weeks

  19. Phase II Dose Expansion Cohort:Correlation between biomarker expression levels (FoxP3, PD-L1, CCR8, CD8) and the anti-tumor activity of LM-108 as monotherapy or in combination with anti-tumor therapies.

    Time frame: 152 Weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Oct 2026, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 26, 2022
StartActual
Aug 26, 2022
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05518045
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Aug 26, 2022
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Sep 3, 2026

Study contacts

Lin Shen
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cafelkibart

Start the discussion